09/09/2010 Stopping antiplatelet therapy after a drug active stent placement increases high risk of thrombosis 09/09/2010 Researchers from Vall d'Hebron Research Institute (VHIR) lead a study showing epidemiological data on the causes and consequences of noncompliance with antiplatelet therapy with platelet after placement of a drug-eluting stent or drug active stent. Due to the severity of the effects of stopping treatment and the lack of information available about the reasons for this suspension, the Epidemiology Unit of the Heart Area of the Hospital Vall Hebron, under the direction of Dr. Ignacio Ferreira, conducted a study which have analyzed the causes to detect the problem and look for solutions. The study was published this week in 'Circulation'. Researchers from Vall d'Hebron Research Institute (VHIR) lead a study showing epidemiological data on the causes and consequences of noncompliance with antiplatelet therapy with platelet after placement of a drug-eluting stent or drug active stent. Due to the severity of the effects of stopping treatment and the lack of information available about the reasons for this suspension, the Epidemiology Unit of the Heart Area of the Hospital Vall Hebron, under the direction of Dr. Ignacio Ferreira, conducted a study which have analyzed the causes to detect the problem and look for solutions. The study was published this week in 'Circulation'. Twitter LinkedIn Facebook Whatsapp
